CHEMOTHERAPY
Online ISSN : 1884-5894
Print ISSN : 0009-3165
ISSN-L : 0009-3165
産婦人科領域におけるCS-1170に関する基礎的・臨床的検討
本村 龍太郎中島 久良河野 通久山辺 徹
著者情報
ジャーナル フリー

1978 年 26 巻 Supplement5 号 p. 582-587

詳細
抄録

The present authors have carried out laboratory and clinical investigations of CS-1170 in the field of obstetrics and gynecology, and the results were obtained as follows.
1. CS-1170 was one shot injected intravenously at a dose of 500 mg to 19 cases of pregnant women, and the drug was distributed in the body as follows.
1) Concentration in mother serum The highest value of 52.0 μg/ml was obtained 19 minutes after the administration, then the drug was excreted rapidly, and the level was undetermined after 5 hours and 20 minutes.
2) Concentration in umbilical cord serum
The highest value of 11.5μg/ml was demonstrated in the serum of umbilical cord, being later 1-2 hour than that of mother body. Transfer rate of the drug in umbilical cord serum showed about 1/5 of that in mother serum.
3) Concentration in amniotic fluid
Transfer of the drug in amniotic fluid was recognized from 1 hour and 10 minutes after the administration, the highest value of 4.0 μg/ml was noted after 3 hours and 47 minutes, then the excretion became slow, and the value was undetermined after 13 hours and 18 minutes.
2. Clinical results were obtained as follows: Excellent in 1 case (25%) and good in 3 cases (75%) out of 4 cases of external genital infection (puerperal mastitis 1 case, Bartholin's abscess 2 cases, and episiotomy and lacerated wound infection 1 case); excellent in 1 case (16.7%) and good in 5 cases (83.3%) out of 6 cases of internal genital infection (puerperal fever 2 cases, pelvic peritonitis combined with endometrial-myometritis 3 cases, and pelvic cellulitis 1 case); and good in 2 cases (100%) out of 2 cases of urinary tract infection after radical operation of uterus cancer. Efficacy ratio of the drug was thus 100%(excellent 16.7% and good 83.3%) among 12 cases in total.
CS-1170 was administered by one shot injection or intravenous drip infusion at a dose of 0.5-2g for 3-5 days.
3. As to the side effect of the drug, eruption was observed in 1 case. Clinical tests did not reveal any noteworthy finding.

著者関連情報
© 社団法人日本化学療法学会
前の記事
feedback
Top